Generic Name and Formulations:
Dalfampridine 10mg; ext-rel tabs.
Indications for AMPYRA:
To improve walking in patients with multiple sclerosis (demonstrated by an increase in walking speed).
Swallow whole. ≥18yrs: max 10mg every 12hrs.
<18yrs: not established.
History of seizures. Moderate to severe renal impairment (CrCl ≤50mL/min). Previous allergies to 4-aminopyridine.
Assess renal function before initiation; monitor at least annually. Mild renal impairment (CrCl 51–80mL/min): increased risk of seizures. Discontinue if signs/symptoms of anaphylaxis occurs. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.
Potassium channel blocker.
Discontinue other forms of 4-aminopyridine prior to initiating. Concomitant OCT2 inhibitors (eg, cimetidine) may potentiate the risk of seizures.
UTI, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, MS relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, throat pain; seizures (possible at higher doses), severe allergic reactions.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds